Related Experiment Video
Updated: Jul 9, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Current role of thalidomide in HIV-positive patients with recurrent aphthous ulcerations
1Medically Complex Patient Clinic, University of Texas Dental Branch, Houston, USA.
Abstract:
Among patients with HIV/AIDS, mucosal lesions of unknown etiology such as recurrent aphthous ulcerations (RAUs) often are unresponsive to standard therapies, resulting in substantial morbidity. The literature regarding RAUs suggests that the inflammatory response contributes to its pathogenesis; however, the role of cytokines in this mucosal immune response remains largely unknown. Thalidomide first was marketed as a sedative in the 1950s and withdrawn from the market in 1961 following reports of teratogenicity. Later, it was used as an investigational agent for the treatment of Hansen's disease, Kaposi's sarcoma, myelofibrosis, RAUs, and wasting associated with HIV. Thalidomide's mechanism of action in RAUs still is not understood completely, but it appears to be mediated by inhibition of the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha). This article discusses the current status of thalidomide for treating RAUs in HIV-positive patients. Suggestions regarding the safe and effective prescribing of thalidomide have been included so that dental professionals will be able to treat these patients safely.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Treatment of Ulcerative Colitis in IBD
Retrovirus Life Cycles
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists